135. Outcomes of Kidney Transplantation with a CMV Matching Allocation Schema
Session: Oral Abstract Session: Infections in Transplantation
Thursday, October 5, 2017: 11:45 AM
Room: 05AB

Background:  Cytomegalovirus (CMV) infection continues to be a major cause of morbidity in kidney transplant recipients.  The CMV donor-positive (D+)/recipient-negative (R-) serostatus pairing poses highest risk for CMV disease. 

Methods:  In September 2012 we adopted a CMV matching allocation policy at the centers served by our organ procurement organization, the Pacific Northwest Transplant Bank. CMV serostatus was used as a criterion in determining deceased donor kidney allocation, whereby R- kidney transplant recipients were preferentially paired with a D- organ, and R+ recipients with a R+ organ. We performed a retrospective analysis of CMV-related outcomes for 400 consecutive kidney recipients, 196 prior to (January 1, 2010 – August 31, 2012) & 204 following (September 1, 2012 – December 3, 2014) implementation of the CMV matching allocation schema at our center.  We also looked at waitlist time for patients transplanted during the same period.   

Results:  The percentage of D+/R- transplants performed decreased from 17.3% to 2.5% (p<0.001) after implementation of the CMV matching allocation strategy (Figure 1).  CMV viremia decreased from 13.3% to 5.9% (p=0.0118), and CMV syndrome or disease decreased from 9.2% to 2.9% (p=0.00859) (Table 1).  The percentage of patients treated for CMV infection overall decreased from 10.7% to 5.4% (p=0.0498).

Median days on the waitlist prior to transplantation increased from 793 (PRE) to 944 (POST) due to growing wait list size, but neither R- nor R+ patients appeared to be disadvantaged:  wait times increased from 808.5 to 958 for the R- subset & from 777.5 to 933 for the R+ subset (Figure 2).

Conclusion:  CMV disease occurred infrequently in our cohort, in the context of 6 months of valganciclovir prophylaxis post-transplant & post-prophylaxis preemptive monitoring strategy for our D+/R- recipients.  Following implementation of an allocation schema that took CMV serostatus into account, the rate of CMV infection and antiviral treatment decreased significantly. 

Table 1.





n (%)

n (%)

CMV viremia

26 (13.3)

12 (5.9)


CMV syndrome

13 (6.6)

1 (0.05)


7 D+/R-

4 D+/R+

2 D-/R+

1 D+/R-


CMV disease

5 (2.5)

5 (2.5)


4 D+/R+

1 D+/R-

4 D+/R+

1 D-/R-


# treated for CMV

21 (10.7)

11 (5.4)


Lymphocyte depleting immune suppression

91 (46.4)

46 (22.5)

Lynne Strasfeld, MD1, Debargha Basuli, MD PhD2, Douglas Norman, MD2, Eric Langewisch, MD3, Ali Olyaei, PharmD4 and Joseph Lockridge, MD2, (1)Division of Infectious Disease, Oregon Health & Science University, Portland, OR, (2)Nephrology, Oregon Health & Science University, Portland, OR, (3)Nephrology, University of Nebraska Medical Center, Omaha, NE, (4)Oregon Health Sciences University, Portland, OR


L. Strasfeld, Merck: Independent Contractor , Salary

D. Basuli, None

D. Norman, None

E. Langewisch, None

A. Olyaei, None

J. Lockridge, None

<< Previous Abstract | Next Abstract

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.